In Finland, repaglinide is dominant to nateglinide as combination therapy with metformin for the treatment of type 2 diabetes mellitus inadequately controlled with monotherapy

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.507, 2006-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus

By Guarino Elisa   Nigi Laura   Patti Aurora   Fondelli Cecilia   Dotta Francesco  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 9, 2012-06 ,pp. : 1377-1384

Informa Healthcare

Access to resources Recommend Favorite

Combination of glibenclamide–metformin HCl for the treatment of type 2 diabetes mellitus

By Lamos Elizabeth Mary   Stein Stephanie Aleskow   Davis Stephen N  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 17, 2012-12 ,pp. : 2545-2554

Informa Healthcare

Access to resources Recommend Favorite

Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea

By Aronson Ronnie  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1535-1539

Informa Healthcare

Access to resources Recommend Favorite

Tolerability Profile of Metformin/Glibenclamide Combination Tablets (Glucovance®): A New Treatment for the Management of Type 2 Diabetes Mellitus

By Jaime A. Davidson  

Drug Safety, Vol. 27, Iss. 15, 2004-01 ,pp. : 1205-1216

Adis International

Access to resources Recommend Favorite

Glibenclamide plus metformin combination tablets are effective, convenient and well tolerated in the treatment of type 2 diabetes mellitus

By Derosa Giuseppe  

Drugs & Therapy Perspectives, Vol. 22, Iss. 8, 2006-08 ,pp. : 1-6

Adis International

Access to resources Recommend Favorite